Open access
Open access
Powered by Google Translator Translator

RCT: Low-cost, easy to take antiretroviral treatment based on Dolutegravir as first- or second-Line therapy found to be non-inferior to standard care for treating HIV-1 infection in children.

8 Jan, 2022 | 23:07h | UTC

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Easy-to-take medicine better at suppressing HIV in children – University College London


Commentaries on Twitter


Stay Updated in Your Specialty

No spam, just news.